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ABSTRACT
Complex or co-existing diseases are commonly treated using drug
combinations, which can lead to higher risk of adverse side effects.
The detection of polypharmacy side effects is usually done in Phase
IV clinical trials, but there are still plenty which remain undiscov-
ered when the drugs are put on the market. Such accidents have
been affecting an increasing proportion of the population (15% in
the US now) and it is thus of high interest to be able to predict the
potential side effects as early as possible. Systematic combinatorial
screening of possible drug-drug interactions (DDI) is challenging
and expensive. However, the recent significant increases in data
availability from pharmaceutical research and development efforts
offer a novel paradigm for recovering relevant insights for DDI pre-
diction. Accordingly, several recent approaches focus on curating
massive DDI datasets (with millions of examples) and training ma-
chine learning models on them. Here we propose a neural network
architecture able to set state-of-the-art results on this task—using
the type of the side-effect and the molecular structure of the drugs
alone—by leveraging a co-attentional mechanism. In particular, we
show the importance of integrating joint information from the drug
pairs early on when learning each drug’s representation.
1 INTRODUCTION
Diseases are often caused by complex biological processes which
cannot be treated by individual drugs and thus introduce the need
for concurrent use of multiple medications. Similarly, drug com-
binations are needed when patients suffer from multiple medical
conditions. However, the downside of such treatment (commonly
referred to as polypharmacy) is that it increases the risk of adverse
side effects, caused by the chemical-physical incompatibility of the
drugs. Such drug-drug interactions (DDIs) have become a serious
issue in recent times, affecting nearly 15% of the US population
[12], with treatment costs exceeding $177 billion/year [13].
Detection of polypharmacy side effects remains a challenging task
to this day: systematic combinatorial screening is expensive and,
while the search for such side effects is usually done during clin-
ical testing, the small scale of the trials and the rarity of adverse
DDI means that many adverse drug reactions (ADRs) are unknown
when the drugs reach the market. Moreover, the immense cost of
designing a drug makes it desirable to be able to predict ADRs as
early as possible in the pipeline.
In this work, we propose the use of deep learning to ameliorate this
problem. One of deep learning’s main advantages is the ability to
perform automated feature extraction from raw data. This means
that, provided the existence of sufficiently large datasets, models
can now be developed without depending on manually engineered
features, which are expensive to obtain and require expert domain
knowledge [16]. In this work, we leverage such a large dataset [39],
consisting of ∼4.5M examples of (drug, drug, interaction) tuples, to
demonstrate that these models are indeed viable in the DDI domain.
By looking at the chemical structures of the drug pairs, our model
learns drug representations which incorporate joint drug-drug infor-
mation. We then predict whether a drug-drug pair would cause side
effects and what their types would be. Our method outperforms
previous state-of-the-art models in terms of predictive power, while
using just the molecular structure of the drugs. It thus allows for
the method to be applied to novel drug combinations, as well as
permitting the detection to be performed at the preclinical phase
rather than in the drug discovery phase, leveraging clinical records.
Our approach paves the way to a new and promising direction
in analysing polypharmacy side effects with machine learning, that
is in principle applicable to any kind of interaction discovery task
between structured inputs (such as molecules), especially under
availability of large quantities of labelled examples.
2 RELATEDWORK
Our work finds itself at the intersection of two domains: compu-
tational methods for prediction of side effects caused by DDI and
neural networks for graph-structured data. As such, a review of
related advances in each area will be presented here.
As manually examining drug combinations and their possible side
effects cannot be done exhaustively, computational methods were
first developed to identify the drug pairs which create a response
higher than the additive response they would cause if they did
not interact [34]. This was previously done by framing the task
as a binary classification problem and designing machine learning
models (naïve Bayes, logistic regression, support vector machines)
which predict the probability of a DDI, using the measurement of
cell viability [8, 20, 35, 37, 48]. Other related approaches considered
dose-effect curves [3, 38] or synergy and antagonism [24].
An alternative way of approaching the task is provided by mod-
els which use the assumption that drugs with similar features are
more likely to interact [17, 20, 25, 26, 37, 42, 47]. Using features
such as the chemicals’ structures, individual drug side effects and
interaction profile fingerprints, the models use unsupervised or
semi-supervised techniques (clustering, label propagation) in order
to find DDIs. Alternatively, restricted Boltzmann machines and
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Figure 1: An overview of the binary (left) and multi-label (right) drug-drug interaction (DDI) task. In both cases,
two drugs (represented as their molecular structures) are provided to the model in order to predict existence or
absence of adverse interactions. For binary classification, the DDI predictor is also given a particular side effect
as input, and is required to specifically predict existence or absence of it. For multi-label classification, the DDI
predictor simultaneously predicts existence or absence of all side-effects under consideration.
matrix factorization were used to combine different types of simi-
larities by learning latent representations [7, 43].
However, all these methods are limited to either providing the
likelihood of a DDI (but not its type if one exists), or lack applica-
bility in inductive settings. Decagon [46] and the Multitask Dyadic
Prediction in [21] are two methods which overcome these chal-
lenges, and are thus going to be used as baselines against which our
work will be compared. Multitask Dyadic Prediction is a proximal
gradient method which uses substructure fingerprints to construct
the drug feature representations. Similarly to our work, it has access
only to the chemical structure of the drug.
Decagon, on the other hand, improves predictive power further by
including additional relational information with protein targets of
interest. Specifically, Decagon leverages this information by apply-
ing a graph convolutional neural network architecture over a graph
corresponding to the interactions between pairs of drugs, pairs of
proteins and drug-protein pairs, treating discovery of novel DDIs
as a link prediction task in the graph. While the protein-related
auxiliary information is highly beneficial for the algorithm to use,
it could also be expensive to obtain.
Compared to previous methods, our contribution is a model which
learns a robust representation of drugs by leveraging joint infor-
mation early on in the learning process. This allows it to bring an
improvement in terms of predictive power, while maintaining an
inductive setup where the model indicates the types of the possible
side effects by just looking at chemical structure of the drugs.
Ourmodel builds up on a large existing body of work in graph convo-
lutional networks [6, 11, 14, 23, 41], that have substantially advanced
the state-of-the-art in many tasks requiring graph-structured input
processing (such as the chemical representation [9, 14, 45] of the
drugs leveraged here). Furthermore, we build up on work propos-
ing co-attention [10, 27] as a mechanism to allow for individual
set-structured datasets (such as nodes in multimodal graphs) to in-
teract. Overall, these (and related) techniques correspond to one of
the latest major challenges of machine learning [4, 5, 18], with trans-
formative potential across a wide spectrum of potential applications
(not only limited to the biochemical domain).
3 ARCHITECTURE
In this section, we will present the main building blocks used within
our architecture for drug-drug interaction prediction. This will span
a discussion of the way the input to the model is encoded, followed
by an overview of the individual computational steps of the model.
Lastly, we will specify the loss functions optimised by the models.
3.1 Inputs
The drugs, dx , are represented as graphs consisting of atoms, a(dx )i
as nodes, and bonds between those atoms
(
a
(dx )
i ,a
(dx )
j
)
as edges.
For each atom, the following input features are recorded: the atom
number, the number of hydrogen atoms attached to this atom, and
the atomic charge. For each bond, a discrete bond type (e.g. single,
double etc.) is encoded as a learnable input edge vector, e(dx )i j . The
side effects, sez , are one-hot encoded from a set of 964 side effects.
The input to our model varies depending on whether we are per-
forming binary classification for a given side effect, or multi-label
classification for all side effects at once:
• For binary classification (Figure 1 (Left)), the input to our
model is a triplet of two drugs and a side effect (dx ,dy , sez ),
requiring a binary decision on whether drugs x and y ad-
versely interact to cause side effect z.
• For multi-label classification (Figure 1 (Right)), the input
to our model is a pair of two drugs (dx ,dy ), requiring 964
simultaneous binary decisions on whether drugs x and y
adversely interact to cause each of the considered side effects.
Note that, in terms of learning pressure, this model requires
more robust joint representations of pairs of drugs—as they
need to be useful for all side-effect predictions at once.
In both cases, the model returns a score associated with the likeli-
hood of a particular side effect occurring (higher scores implying
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Figure 2: The illustration of a single step of message passing (computing the inner message, (dx )mti ), and co-
attention (computing the outer message (dx )ntu ) on two nodes (i and u) of drug x .
larger likelihoods). This score can then be appropriately thresholded
to obtain a viable classifier.
3.2 Message passing
Within each of the two drugs separately, our model applies a series
of message passing [14] layers. Herein, nodes are allowed to send
arbitrary vector messages to each other along the edges of the graph,
and each node then aggregates all the messages sent to it.
Let (dx )hti denote the features of atom i of drug x , at time step
t . Specially, initially these are set to projected input features, i.e.:
(dx )h0i = fi
(
a
(dx )
i
)
(1)
where fi is a small multilayer perceptron (MLP) neural network.
In all our experiments, this MLP (and all subsequently referenced
MLPs and projections) projects its input to 32 features.
Considering atoms i and j of drug x , connected by a bond with
edge vector e(dx )i j , we start by computing the message,
(dx )mti j , sent
along the edge j → i . The message takes into account both the
features of node j and the features of the edge between i and j:
(dx )mti j = f
t
e
(
e
(dx )
i j
)
⊙ f tv
((dx )ht−1j ) (2)
where f te and f tv are small MLPs, and ⊙ is elementwise vector-
vector multiplication.
Afterwards, every atom i aggregates the messages sent to it via
summation. This results in an internal message for atom i , (dx )mti :
(dx )mti =
∑
∀j ∈N (i)
(dx )mti j (3)
where the neighbourhood, N (i), defines the set of atoms linked to i
by an edge.
3.3 Co-attention
Message passing provides a robust mechanism for encoding within-
drug representations of atoms. For learning an appropriate joint
drug-drug representation, however, we allow atoms to interact
across drug boundaries via a co-attentional mechanism [10].
Consider two atoms, i and j, of drugs x and y, respectively. Let
their features at time step t be (dx )hti and
(dy )htj , just as before. For
every such pair, we compute an attentional coefficient, α ti j using a
simplified version of the Transformer [40] attention mechanism:
α ti j = softmaxj
(〈
Wtk
(dx )ht−1i ,W
t
k
(dy )ht−1j
〉)
(4)
whereWtk is a learnable projection matrix, ⟨·, ·⟩ is the inner product,
and the softmax is taken across all nodes j from the second drug.
The coefficients α ti j may be interpreted as the importance of atom
j’s features to atom i .
These coefficients are then used to compute an outer message for
atom i of drug x , (dx )nti , expressed as a linear combination (weighted
by α ti j ) of all (projected) atom features from drug y:
(dx )nti =
∑
∀j ∈dy
α ti j ·Wtv (dy )ht−1j (5)
whereWtv is a learnable projection matrix.
It was shown recently that multi-head attention can stabilise the
learning process, as well as learn information at different conceptual
levels [33, 41]. As such, the mechanism of Equation 5 is indepen-
dently replicated acrossK attention heads (we choseK = 8), and the
resulting vectors are concatenated and MLP-transformed to provide
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Figure 3: A high-level overview of our DDI
model. The next-level features of atom i
of drug x , (dx )hti , are derived by combining
its input features, (dx )ht−1i , its inner message,(dx )mti , computed using message passing, and
its outer message, (dx )nti , computed using co-
attention over the second drug, dy .
the final outer message for each atom.
(dx )nti = f
t
o
©­­«
K∥
k=1
∑
∀j ∈dy
(k )α ti j · (k)Wtv (dy )ht−1j
ª®®¬ (6)
where f to is a small MLP and ∥ is featurewise vector concatenation.
The computation of Equations 4–6 is replicated analogously for
outer messages from drug x to atoms of drug y.
We have also attempted to use other popular attention mechanisms
for computing the α ti j values—such as the original Transformer
[40], GAT-like [41] and tanh [2] attention—finding them to yield
weaker performance than the approach outlined here.
A single step of message passing and co-attention, as used by our
model, is illustrated by Figure 2.
3.4 Update function
Once the inner messages, (dx )mti (obtained through message pass-
ing), as well as the outer messages, (dx )nti (obtained through co-
attention) are computed for every atom i of each of the two drugs
(dx /dy ), we use them to derive the next-level features, (dx )hti , for
each atom.
At each step, this is done by aggregating (via summation) the pre-
vious features (representing a skip connection [19]), the inner mes-
sages and outer messages, followed by layer normalisation [1]:
(dx )hti = LayerNorm
((dx )ht−1i + (dx )mti + (dx )nti ) (7)
The operations of Equations 2–7 are then repeated for T propaga-
tion steps—here, we set T = 3. Refer to Figure 3 for a complete
visualisation of our architecture.
As will be demonstrated in the Results section, using co-attention to
enable the model to propagate the information between two drugs
from the beginning—thus learning a joint representation of the
drugs—valuably contributes to the predictive power of the model.
3.5 Readout and Scoring
As we’re making predictions on the level of entire drug-drug pairs,
we need to compress individual atom representations into drug-
level representations. In order to obtain the drug-level vectors dx ,
we apply a simple summation of its constituent atom feature vectors
after the final layer (i.e. afterT propagation steps have been applied):
dx =
∑
∀j ∈dx
fr
((dx )hTj ) (8)
where fr is a small MLP.
Once the drug vectors are computed for both dx and dy , these
can be used to make predictions on side effects—and the exact
setup varies depending on the type of classification.
3.5.1 Binary classification. In the binary classification case, the
side effect vector sez is provided as input.We then leverage a scoring
function f similar to the one used by Yoon et al. [44] to express the
likelihood of this side effect occuring:
f (dx ,dy , sez ) =
Mhdx + sez −Mtdy22 +Mhdy + sez −Mtdx 22
(9)
where ∥ · ∥2 is the L2 norm, andMh andMt represent the head node
and tail node space mapping matrices, respectively.
The model is then trained end-to-end with gradient descent to
optimise a margin-based ranking loss:
L =
∑
dx ,dy,sez
∑
˜dx ,d˜y,sez
max(0,γ − f (dx ,dy , sez ) − f ( ˜dx , d˜y , sez )))
(10)
where (dx ,dy ) is a drug-drug pair exhibiting side effect sez , and
( ˜dx , d˜y ) is a drug-drug pair not exhibiting it. γ > 0 is the margin
hyperparameter.
3.5.2 Multi-label classification. Here, all side effects are predicted
simultaneously, and accordingly we define a prediction layer, param-
etrised by a learnable weight matrix Wp and bias bp . This layer
consumes the concatenation of the two drug vectors and projects
it into a score for each of the 964 side effects. These scores are then
converted into probabilities, yzxy , of each side effect, z, occurring
between drugs x and y using the logistic sigmoid nonlinearity, σ ,
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applied elementwise:
yzxy = σ
(
Wp [dx ∥dy ] + bp
)
z
(11)
We can then once again train the model end-to-end with gradient
descent, using binary cross-entropy against the ground truth value,
yˆzxy (which is a binary label indicating whether side effect z actually
occurs between drugs x and y). The loss function is as follows:
LBCE =
∑
dx ,dy,z
yˆzxy logyzxy +
(
1 − yˆzxy
)
log
(
1 − yzxy
)
(12)
4 DATASET AND PREPROCESSING
The drug-drug interaction data was chosen to be in agreement with
the dataset used by Decagon [46]. It is obtained through filtering
the TWOSIDES side-effect dataset [39], which consists of associa-
tions which cannot be clearly attributed to either drug alone (that is,
those side-effects reported for any individual drug in the OFFSIDE
dataset [39]) and it comprises 964 polypharmacy side-effect types
that occurred in at least 500 drug pairs.
The data format used within the dataset is: (1) The compound
ID of drug 1; (2) The compound ID of drug 2; (3) Side effect concept
identifier; (4) Side effect name. In order to obtain the drug-related
features, we look up the compound IDs in the PubChem database.
This provides us with the molecular structure of each drug:
• Atoms, including type, charge and coordinates for each atom;
• Bonds, including type and style for each bond;
• SMILES string.
In order to compensate for the fact that TWOSIDES contains only
positive samples, appropriate negative sampling is performed for
the binary classification task:
• During training, tuples ( ˜dx , d˜y , sez ), where ˜dx and sez are
chosen from the dataset and d˜y is chosen at random from the
set of drugs different fromdy in the true samples ( ˜dx ,dy , sez ).
• During validation and testing, we simply randomly sam-
ple two distinct drugs which do not appear in the positive
dataset.
The full dataset consists of 4,576,785 positive examples. As we aim
to sample a balanced number of positive and negative examples, the
overall dataset size for training our model is 9,153,570 examples.
5 EXPERIMENTAL SETUP
As previously described, our model consists of T = 3 propaga-
tion blocks (featuring a message-passing layer followed by a co-
attentional layer with K = 8 attention heads). Each block computes
32 intermediate features. To further regularise the model, dropout
[36] withp = 0.2 is applied to the output of every intermediate layer.
The model is initialised using Xavier initialisation [15] and trained
on mini-batches of 200 drug-drug pairs, using the Adam SGD opti-
miser [22] for 30 epochs. The learning rate after t iterations, ηt , is
derived using an exponentially decaying schedule:
ηt = 0.001 · 0.96t ·10−6 (13)
We will refer to this model asMHCADDI (multi-head co-attentive
drug-drug interactions), andMHCADDI-ML for multi-label classi-
fication. We compare our method with the following baselines:
Table 1: Comparative evaluation results after
stratified 10-fold crossvalidation.
AUROC
Drug-Fingerprints [21] 0.744
RESCAL [30] 0.693
DEDICOM [31] 0.705
DeepWalk [32] 0.761
Concatenated features [46] 0.793
Decagon [46] 0.872
MHCADDI (ours) 0.882
MHCADDI-ML (ours) 0.819
• The work of Jin et al. [21] (to be referred to asDrug-Fingerpri-
nts), where binary classification is performed through analys-
ing the molecular fingerprints of drugs.
• Decagon [46], where drug-protein interactions and protein-
protein interactions are considered in as additional inputs to
the model, and the entire interaction graph is simultaneously
processed by a graph convolutional network.
• We also report the results of all the baselines used byDecagon,
such as the RESCAL [30] and DEDICOM [31] tensor decom-
position methods and DeepWalk [32].
In addition, we perform detailed ablation studies to stress the im-
portance of various components of MHCADDI. Specifically, the
following baselines are also evaluated:
• An architecture (to be referred to as MPNN-Concat) where
the drug representations are learnt separately, solely using
internal message passing. The side effect probability is then
computed by concatenating the individual drug representa-
tions. This serves to demonstrate the importance of jointly
learning the drug embeddings (by e.g. co-attention).
• An architecture (to be referred to as Late-Outer) where the
outer messages are only considered at the end of the node
updating procedure. Each propagation step t of the MPNN
function creates “clusters” with information from neighbour-
ing atomswithin the same drug at a distance of at most t hops
away. The outer messages are then computed at different
granularity levels and integrated at the end of the pipeline.
Similarly as before, this serves to demonstrate the impor-
tance of simultaneously performing internal and external
feature extraction.
• An architecture (to be referred to as CADDI ) where there is
only K = 1 attention head.
We omit comparisons with traditional machine learning baselines
(such as support vector machines or random forests) as prior work
[21] has already found them to be significantly underperforming
compared to neural network approaches on this task.
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Table 2: Ablation study for various aspects of
the MHCADDI model.
AUROC
MPNN-Concat 0.661
Late-Outer 0.724
CADDI 0.778
MHCADDI 0.882
Table 3: Top-5 and bottom-5 side effects byAU-
ROC values.
Highest
Side effect AUROC
Tooth impacted 0.903
Nasal polyp 0.902
Cluster headache 0.900
Balantis 0.892
Dysphemia 0.889
Lowest
Side effect AUROC
Neonatal respiratory distress syndrome 0.670
Aspergillosis 0.683
Obstructive uropathy 0.690
Icterus 0.712
HIV disease 0.712
6 RESULTS
6.1 Quantitative Results
We perform stratified 10-fold crossvalidation on the derived dataset
to evaluate our models and compare them against previously pub-
lished baselines. For each model, we report the area under the
receiver operating characteristic (ROC) curve averaged across the
10 folds. The results of our study may be found in Tables 1–2.
From this study, we may conclude that learning joint drug-drug
representations by simultaneously combining internal message-
passing layers and co-attention between drugs is a highly beneficial
approach, consistently outperforming the strong baselines consid-
ered here (even when additional data sources are used, as in the
case of Decagon). Furthermore, through observing the compar-
isons between several variants of our architecture, more detailed
conclusions easily follow:
• The fact that all our co-attentive architectures outperformed
MPNN-Concat implies that it is beneficial to learn drug-drug
representations jointly rather than separately.
• Furthermore, the outperformance of Late-Outer by (MH)CA-
DDI further demonstrates that it is useful to provide the
cross-modal information earlier in the learning pipeline.
Figure 4: t-SNE projections of 200 learnt drug-
drug representations, across 9 side-effects.
Each side effect is colour-coded with a shade
of red for positive drug-drug pairs and a shade
of green for negative pairs.
• Lastly, the comparative evaluation of MHCADDI against
CADDI further shows the benefit of inferring multiple mech-
anisms of drug-drug interaction simultaneously, rather than
anticipating only one.
Finally, we can observe that, despite the additional learning chal-
lenges present when doing multi-label classification (in the case
of MHCADDI-ML), our jointly learned representations are still
competitive with all other baselines. In particular, our method sig-
nificantly outperforms Drug-Fingerprints—which also uses a multi-
label objective.
As an additional ablation study, similarly to the analysis performed
by Decagon [46], for one testing fold we stratified the predictions
of our model across all side effects, computing side effect-level
AUROC values. These values are given for five of the best- and
worst- performing side effects in 3. There is a slight correpondence
to the performance of Decagon—with Icterus appearing as one of
their worst-performing side effects and a different polyp appearing
as one of their best-performing ones. Overall, we do not find that
our distribution of per-side-effect AUROC values deviates from the
mean value any more substantially than what was reported for
Decagon. This implies that our model does not drastically sacrifice
performance on some side-effects—at least, not compared to the
prior baseline methods which use auxiliary data sources.
6.2 Qualitative Results
The effectiveness of the learnt joint representations may be inves-
tigated qualitatively as well, and to that end, we have devised a
controlled visualisation experiment. Our objective is to investigate
the distribution of learnt drug-drug embeddings with respect to
individual side effects.
We start with a pre-trained MHCADDI model. For each side ef-
fect in a sample of 10, we have randomly sampled 100 drug-drug
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Figure 5: t-SNE projection of 2000 learnt drug-
drug representations, sampled to cover 10 side
effects. Each side effect is colour-coded with a
shade of red for positive drug-drug pairs and
a shade of green for negative drug-drug pairs.
pairs exhibiting this side effect, and 100 drug-drug pairs not ex-
hibiting it (both unseen by the model during training). For these
pairs, we derived their embeddings, and projected them into two
dimensions using t-SNE [29].
The visualised embeddings may be seen in Figure 4 for individ-
ual side-effects, and Figure 5 for a combined plot. These plots
demonstrate that, across a single side-effect, there is a discernible
clustering in the projected 2D space of drug-drug interactions. Fur-
thermore, the combined plot demonstrates that strongly side-effect
inducing drug-drug pairs tend to be clustered together, and away
from the pairs that do not induce side-effects.
7 CONCLUSIONS
In this work, we have presented a graph neural network architec-
ture which sets state-of-the-art results for predicting the possible
polypharmacy side effects of drug combinations, using solely the
molecular structure information of drug pairs. By performing mes-
sage passing within each drug, as well as co-attending over the
other drug’s structure, we demonstrated the power of integrating
joint drug-drug information during the representation learning
phase for individual drugs. Future directions could include apply-
ing such cross-modal architectures to predicting interactions in
different kinds of networks (such as language or social) where the
components of different networks interact with each other.
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A HYPERPARAMETERS
In the interests of reproducibility, in this supplementary material
we detail all the hyperparameters used for training and evaluating
our MHCADDI model described above.
For each atom, its features a(dx )i are obtained by concatenating
the specified input features with a learnable embedding (unique to
each atom) of 32 dimensions.
The input node projection function, fi , is a single-layer MLP with
no bias:
fi (x) =Wfi x (14)
computing 32 features, followed by dropout with p = 0.2.
The learnable edge embeddings, e(dx )i j , are of 32 features, and dropout
with p = 0.2 is immediately applied to them once retrieved.
The node projection MLP for message passing, f tv , is a single-layer
MLP with no bias:
f tv (x) =Wf tv x (15)
computing 32 features, followed by dropout with p = 0.2.
The edge projection MLP for message passing, f te , is a two-layer
MLP with leaky ReLU [28] activations:
f te (x) = LeakyReLU
(
W2f te LeakyReLU
(
W1f te x + b
1
f te
)
+ b2f te
)
(16)
Both layers compute 32 features, and dropout with p = 0.2 is ap-
plied to both of their outputs.
The key/value projection matrices, Wtk and W
t
v , of each atten-
tion head, compute 32 features each.
The outer message MLP for co-attention, f to , is a single-layer MLP
with the leaky ReLU activation:
f to (x) = LeakyReLU
(
Wf to x + bf to
)
(17)
computing 32 features, followed by dropout with p = 0.2.
The readout projection MLP, fr , is a single-layer MLP with the
leaky ReLU activation:
fr (x) = LeakyReLU
(
Wfr x + bfr
)
(18)
The head node and tail node mapping matrices,Mh andMt (used
within the computation of side effect likelihoods), compute 32 fea-
tures each.
The margin hyperparameter γ has been set to γ = 1.
